Computational-experimental approach to drug-target interaction mapping: A case study on kinase inhibitors
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Computational-experimental approach to drug-target interaction mapping : A case study on kinase inhibitors. / Cichonska, Anna; Ravikumar, Balaguru; Parri, Elina; Timonen, Sanna; Pahikkala, Tapio; Airola, Antti; Wennerberg, Krister; Rousu, Juho; Aittokallio, Tero.
I: PLOS Computational Biology, Bind 13, Nr. 8, 08.2017, s. e1005678.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Computational-experimental approach to drug-target interaction mapping
T2 - A case study on kinase inhibitors
AU - Cichonska, Anna
AU - Ravikumar, Balaguru
AU - Parri, Elina
AU - Timonen, Sanna
AU - Pahikkala, Tapio
AU - Airola, Antti
AU - Wennerberg, Krister
AU - Rousu, Juho
AU - Aittokallio, Tero
PY - 2017/8
Y1 - 2017/8
N2 - Due to relatively high costs and labor required for experimental profiling of the full target space of chemical compounds, various machine learning models have been proposed as cost-effective means to advance this process in terms of predicting the most potent compound-target interactions for subsequent verification. However, most of the model predictions lack direct experimental validation in the laboratory, making their practical benefits for drug discovery or repurposing applications largely unknown. Here, we therefore introduce and carefully test a systematic computational-experimental framework for the prediction and pre-clinical verification of drug-target interactions using a well-established kernel-based regression algorithm as the prediction model. To evaluate its performance, we first predicted unmeasured binding affinities in a large-scale kinase inhibitor profiling study, and then experimentally tested 100 compound-kinase pairs. The relatively high correlation of 0.77 (p < 0.0001) between the predicted and measured bioactivities supports the potential of the model for filling the experimental gaps in existing compound-target interaction maps. Further, we subjected the model to a more challenging task of predicting target interactions for such a new candidate drug compound that lacks prior binding profile information. As a specific case study, we used tivozanib, an investigational VEGF receptor inhibitor with currently unknown off-target profile. Among 7 kinases with high predicted affinity, we experimentally validated 4 new off-targets of tivozanib, namely the Src-family kinases FRK and FYN A, the non-receptor tyrosine kinase ABL1, and the serine/threonine kinase SLK. Our sub-sequent experimental validation protocol effectively avoids any possible information leakage between the training and validation data, and therefore enables rigorous model validation for practical applications. These results demonstrate that the kernel-based modeling approach offers practical benefits for probing novel insights into the mode of action of investigational compounds, and for the identification of new target selectivities for drug repurposing applications.
AB - Due to relatively high costs and labor required for experimental profiling of the full target space of chemical compounds, various machine learning models have been proposed as cost-effective means to advance this process in terms of predicting the most potent compound-target interactions for subsequent verification. However, most of the model predictions lack direct experimental validation in the laboratory, making their practical benefits for drug discovery or repurposing applications largely unknown. Here, we therefore introduce and carefully test a systematic computational-experimental framework for the prediction and pre-clinical verification of drug-target interactions using a well-established kernel-based regression algorithm as the prediction model. To evaluate its performance, we first predicted unmeasured binding affinities in a large-scale kinase inhibitor profiling study, and then experimentally tested 100 compound-kinase pairs. The relatively high correlation of 0.77 (p < 0.0001) between the predicted and measured bioactivities supports the potential of the model for filling the experimental gaps in existing compound-target interaction maps. Further, we subjected the model to a more challenging task of predicting target interactions for such a new candidate drug compound that lacks prior binding profile information. As a specific case study, we used tivozanib, an investigational VEGF receptor inhibitor with currently unknown off-target profile. Among 7 kinases with high predicted affinity, we experimentally validated 4 new off-targets of tivozanib, namely the Src-family kinases FRK and FYN A, the non-receptor tyrosine kinase ABL1, and the serine/threonine kinase SLK. Our sub-sequent experimental validation protocol effectively avoids any possible information leakage between the training and validation data, and therefore enables rigorous model validation for practical applications. These results demonstrate that the kernel-based modeling approach offers practical benefits for probing novel insights into the mode of action of investigational compounds, and for the identification of new target selectivities for drug repurposing applications.
KW - Algorithms
KW - Computational Biology/methods
KW - Databases, Factual
KW - Drug Discovery/methods
KW - Humans
KW - Models, Statistical
KW - Protein Binding
KW - Protein Kinase Inhibitors/chemistry
KW - Reproducibility of Results
U2 - 10.1371/journal.pcbi.1005678
DO - 10.1371/journal.pcbi.1005678
M3 - Journal article
C2 - 28787438
VL - 13
SP - e1005678
JO - P L o S Computational Biology (Online)
JF - P L o S Computational Biology (Online)
SN - 1553-734X
IS - 8
ER -
ID: 199422848